simendan has been researched along with isoproterenol in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Burkhoff, D; Knecht, M; Packer, M; Stennett, R; Todaka, K; Wang, J; Yi, GH | 1 |
| Alpert, NR; Hasenfuss, G; Holubarsch, C; Just, H; Kretschmann, B; Pieske, B | 1 |
| Endoh, M; Sato, S; Sawada, H; Sugawara, H; Talukder, MA | 1 |
| Bodi, A; Edes, I; Facsko, A; Kovacs, L; Kranias, EG; Kristof, E; Papp, JG; Papp, Z; Szigeti, G | 1 |
| Endoh, M; Takahashi, R; Talukder, MA | 2 |
| Brixius, K; Reicke, S; Schwinger, RH | 1 |
| Bódi, A; Edes, I; Papp, Z; Szilágyi, S | 1 |
| Angus, JA; Crack, PJ; Royse, CF; Soeding, PF; Wright, CE | 1 |
| Barrett, CJ; Beil, M; Budgett, DM; Fu, F; Guild, SJ; Malpas, SC; McCormick, D; Rigel, DF; Stehlin, E; Whalley, G | 1 |
| Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T | 1 |
| El-Kherbetawy, MK; Makary, S; Tawfik, MK | 1 |
| Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F | 1 |
| Burton, F; Dietrichs, ES; Ghasemi, M; Selli, AL; Smith, G; Watters, T | 1 |
14 other study(ies) available for simendan and isoproterenol
| Article | Year |
|---|---|
Effects of levosimendan on myocardial contractility and oxygen consumption.
Topics: Animals; Calcium; Cardiotonic Agents; Coronary Vessels; Dogs; Ferrets; Hydrazones; In Vitro Techniques; Isoproterenol; Myocardial Contraction; Myocardium; Oxygen Consumption; Pyridazines; Rats; Simendan; Systole; Vasodilation | 1996 |
Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics.
Topics: Adrenergic beta-Agonists; Aequorin; Animals; Calcium; Cardiotonic Agents; Energy Metabolism; Heart; Heart Ventricles; Humans; Hydrazones; In Vitro Techniques; Intracellular Fluid; Isometric Contraction; Isoproterenol; Male; Myocardial Contraction; Myocardium; Pyridazines; Quinolines; Rabbits; Sensitivity and Specificity; Simendan; Thiadiazines | 1995 |
Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aequorin; Animals; Calcium; Cardiotonic Agents; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug; Heart Ventricles; Hydrazones; Indoles; Isoproterenol; Male; Myocardial Contraction; Papillary Muscles; Pyridazines; Quinolines; Rabbits; Simendan; Thiadiazines | 1998 |
Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function.
Topics: Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Guinea Pigs; Heart; Hydrazones; Isoproterenol; Muscle Proteins; Myocardium; Phosphorylation; Pyridazines; Quinolines; Simendan; Thiadiazines; Ventricular Function, Left | 1998 |
Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acetamides; Aequorin; Animals; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Hydrazones; Isoproterenol; Male; Myocardial Contraction; Papillary Muscles; Pyridazines; Rabbits; Simendan; Stimulation, Chemical; Ventricular Function, Right | 2000 |
Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium.
Topics: Acetamides; Animals; Bupranolol; Calcium; Cardiotonic Agents; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; Female; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Pyridazines; Simendan | 2000 |
Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium.
Topics: Calcium; Cardiotonic Agents; Cyclic AMP; Fluorescent Dyes; Fura-2; Heart; Heart Failure; Heart Transplantation; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Muscle Fibers, Skeletal; Muscle Relaxation; Myocardial Contraction; Pyridazines; Reference Values; Simendan; Systole; Ventricular Function, Left | 2002 |
The cardiotonic effects of levosimendan in guinea pig hearts are modulated by beta-adrenergic stimulation.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Cells, Cultured; Culture Techniques; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Guinea Pigs; Heart Ventricles; Hydrazones; Isometric Contraction; Isoproterenol; Myocardial Contraction; Myocytes, Cardiac; Pyridazines; Receptors, Adrenergic, beta; Simendan; Ultrasonography; Ventricular Function | 2003 |
Levosimendan preserves the contractile responsiveness of hypoxic human myocardium via mitochondrial K(ATP) channel and potential pERK 1/2 activation.
Topics: Adrenergic beta-Agonists; Apoptosis; Caspase 3; Cell Hypoxia; Cytochromes c; Enzyme Activation; Heart Atria; Humans; Hydrazones; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Isoproterenol; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle Contraction; Myocardium; Oxygen; p38 Mitogen-Activated Protein Kinases; Phosphoproteins; Potassium Channels; Proto-Oncogene Proteins c-akt; Pyridazines; Simendan | 2011 |
Chronic measurement of left ventricular pressure in freely moving rats.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channel Blockers; Dobutamine; Heart Rate; Hydrazones; Isoproterenol; Male; Pyridazines; Rats; Rats, Wistar; Simendan; Telemetry; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure; Verapamil | 2013 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines | 2014 |
Cardioprotective and Anti-Aggregatory Effects of Levosimendan on Isoproterenol-Induced Myocardial Injury in High-Fat-Fed Rats Involves Modulation of PI3K/Akt/mTOR Signaling Pathway and Inhibition of Apoptosis: Comparison to Cilostazol.
Topics: Animals; Apoptosis; Cilostazol; Diet, High-Fat; Disease Models, Animal; Heart Rate; Inflammation Mediators; Isoproterenol; Lipids; Myocardial Infarction; Myocytes, Cardiac; Phosphatidylinositol 3-Kinase; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Simendan; TOR Serine-Threonine Kinases | 2018 |
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.
Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan | 2023 |
Proarrhythmic changes in human cardiomyocytes during hypothermia by milrinone and isoprenaline, but not levosimendan: an experimental in vitro study.
Topics: Cardiotonic Agents; Heart Diseases; Humans; Hydrazones; Hypothermia; Isoproterenol; Milrinone; Myocytes, Cardiac; Pyridazines; Simendan | 2023 |